Gordon ReidAmgen Inc.AMGNBUYJan 26, 2017

Fifteen of its approved products had double-digit revenue growth YOY in last quarter. GLP-1 entrant still not approved, yet showing promise (bit of a wild card). Now trades at 18x PE, and other companies are more competitive on PE. 

Still in his portfolios, still a Buy, but every day he gets up and reviews client holdings with a critical eye.

He added more. Earnings were very good. New therapies have been adding to margins. They beat top and bottom lines and raised guidance. Will hold for a long time.

Extremely well run, innovative. Not expensive, well less than 20x forward PE. Interesting work in biosimilars. His team doesn't have an "edge" in the biotech space, so they'd rather own something like this via an ETF. Nice dividend. If you own it, keep holding.

In the healthcare space, biotech offers more promise than pharma. 

Is really undervalued here and the technicals look great.

Was upgraded today. A leader and gives you exposure in large-cap biotech.

Their pipeline, good earnings and maybe good news about its weight loss drug could send this higher.  It reports Tuesday.

Really likes it. Breaking out to new highs. He'd be a buyer. Next upside resistance is around the $400 level.

He's been talking to their US sales team about biotech and healthcare in general. If they're correct on the broader market call, then biotech should outperform some of the more defensive areas in healthcare into 2027.

Is priced well. They have 15 compounds approved that saw double-digit sales increases.

They have 15 of their products growing at double-digits last quarter. Their GLP-1 drug is in phase 3 testing, not yet on the market. Stable management. Pays an outsized dividend.

They have 15 of their products growing at double-digits last quarter. Their GLP-1 drug is in phase 3 testing, not yet on the market. Stable management. Pays an outsized dividend.

They have 15 of their products growing at double-digits last quarter. Their GLP-1 drug is in phase 3 testing, not yet on the market. Stable management. Pays an outsized dividend.

It is a biotech company and its pipeline was aging. Like other drug companies it has gone out and built new or rebuilt its pipeline for new drugs. It is interesting and he likes it but it is not his favourite in the space.

Up 20% from its late-September lows and 12% the past 3 months. Last week, they reported a blowout quarter and this past weekend reporting promises results for their cholesterol drug

They delivered a good quarter last night and some good medicines, but they need to tell a better story and need to do something. Are few biotechs he'd buy now apart from Eli Lilly.